Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, gives an overview of current unmet needs within the field of uveal melanoma. Novel treatment strategies for this subtype of melanoma are limited with tebentafusp, a bispecific fusion protein for HLA-A*2-positive patients and isolated hepatic perfusion (IHP) being the only options. Dr Bagge highlights the need for additional therapies and mentions the phase I SCANDIUM II trial (NCT04463368), which will investigate IHP with ipilimumab and nivolumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть